mented with 10% fetal bovine serum (FBS), 1% L-glutamine, and 1% sodium hypoxanthine and thymidine,* either in 175 cm 2 flasks or 3-L stir flasks. After 4 or 5 days of growth at a cell density of 1 to 2 ϫ 10 6 /ml, the supernatants were harvested by centrifugation for 10 minutes at 500 G to remove any remaining cells.
SK-MG-1 Cell Line
The human glioma cell line SK-MG-1 (originally designed AJ 19 ) was grown under standard conditions, as previously described. 2 To study the effects of culture split ratio on surface labeling, SK-MG-1 cells were grown and passaged in 75-cm 2 flasks at split ratios of 0, 1:2, 1:4, 1:8, 1:16, 1:32, and 1:64 for 3 days prior to harvesting and analysis by flow cytometry.
Flow Cytometry
Labeling cells for flow cytometry was conducted as previously described. 2 Analysis and sorting were performed on a flow cytometer using an argon laser delivering 15 mW of 488-nm light for excitation. † The emitted signals from fluorescein isothiocyanate (FITC) corresponding to antibody labeling were collected through a 525-nm bandpass filter. A 575-nm bandpass filter was used for analysis of the yellow-green propidium iodide (PI) signal corresponding to DNA content. Data analysis was performed by computer, ‡ as was analysis of DNA histograms. § Initially, only scraped live cells were labeled for analysis. In subsequent experiments, the cells were detached from culture flasks with 0.54 ethylenediamine tetraacetic acid (EDTA) in phosphate-buffered saline (PBS, pH 7.5), labeled as live cells, then preserved with freshly prepared 2% paraformaldehyde in PBS. Either culture supernatant from a nonspecific human IgM hybridoma 2 (BT27/2D2) or tissue culture medium supplemented with 10% FBS was used as a control. Both controls yielded identical mean green fluorescence. In all experiments, FITC-conjugated goat anti-human IgM (IgG fraction, M chain specific) diluted 1:64 in PBS was used as a second antibody.
In an initial study to determine the viability of the "small" and "large" cell populations of SK-MG-1, 10 6 scraped cells were labeled with PI alone at a final concentration of 50 mg/ml. In all subsequent labeling experiments, PI at a final concentration of 50 mg/ml was added to each labeled sample of live cells just prior to flow cytometry analysis. Gating on live cells was performed as described in the Results section.
To determine the colony-forming efficiency of "small" and "large" cell populations of scraped SK-MG-1 cells, a sterile sort based on the log-FITC versus log-forward scatter distribution was conducted, and the cells were plated in 96-microwell plates and grown under standard conditions. The colony-forming efficiency was determined by the ratio of colonies of greater than 20 cells after 7 days in vitro to the number of cells initially plated.
To determine the effect of culture split ratio on culture viability, areas around "small" and "large" cell populations of SK-MG-1 were established in the log-FITC versus log-forward scatter distribution, and the number of cells in both areas at each passage ratio were compared. The DNA histograms of SK-MG-1 cells at different passage split ratios were determined by trypsinizing confluent cells from tissue culture flasks (to ensure a uniform single-cell preparation), fixing in ice-cold 70% ethanol for 20 minutes, washing once with PBS, incubating at 37˚C with ribonuclease,* cooling to 4˚C, and labeling with PI at a final concentration of 50 mg/ml. 
______________

Results
Determination of Viable and Nonviable Populations of SK-MG-1
We previously reported that flow cytometric analysis of SK-MG-1 glioma cells revealed the presence of two distinct cell populations, designated as "small" and "large" cells based on forward scatter profiles. This observation was based on work with SK-MG-1 glioma cells that had been removed from tissue culture flasks by mechanically scraping the cells from the flask. When SK-MG-1 cells were removed with trypsin or EDTA, which are less harsh on the cells, flow cytometric analysis demonstrated only one cell population (results not shown). Fluorescenceactivated sorting of scraped SK-MG-1 cells revealed that the "small" cells had a 2.0% colony-forming efficiency, whereas the "large" cells were found to have a colonyforming efficiency of 38.0%, almost 20 times greater. When scraped SK-MG-1 glioma cells were labeled with PI alone, we observed an increase in PI fluorescence only among the "small" cells, not among the "large" cells ( Fig.  1 ). Because dead cells will stain 12 with PI, we concluded that the "large" cells of scraped SK-MG-1 are viable and the "small" cell nonviable.
Surface Labeling of Live Cells
When the nonviable "small" cells are backgated onto the forward-scatter versus 90˚-scatter profile, they appear as a separate population below the viable "large" cells on the ordinate. We defined an area around the "large" cells (Region A in Fig 
Cell Cycle-Independent Antigen Expression
We studied the expression of the BT32/A6 antigen throughout the cell cycle by gating on SK-MG-1 glioma cells that were stained with PI ( The observation of labeling throughout each phase of the cell cycle is supported by the finding of increased fluorescence in 100% of viable SK-MG-1 cells. At any given point in time a certain proportion of cells will be in each phase of the cell cycle; thus, the fact that 100% of the cells were labeled indicates that all SK-MG-1 in each phase of the cell cycle were labeled by MAb BT32/A6. We interpret these findings to mean that expression of the BT32/A6 antigen on the surface of live SK-MG-1 cells is unaffected by the cell cycle state of those cells, at the cell passage ratio and culture density we studied. We further studied the effects of altering culture viability, cell growth rate, and cell cycle state on labeling of SK-MG-1 by growing the cells at various passage split ratios.
Antigen Expression and Culture Split Ratio
By passaging confluent cultures of SK-MG-1 glioma cells at split ratios of 0, 1:2, 1:4, 1:8, 1:16, 1:32, and 1:64, then growing the cells under standard conditions for 3 days, we were able to produce significant trends in the following parameters: 1) the ratio of viable to nonviable cells, 2) cell growth rate (Fig. 4), and 3 ) the relative number of cells in G 0 /G 1 , S, and G 2 /M phases of the cell cycle (Fig. 5) . There was an excellent correlation between culture viability (as determined by the ratio of viable to non- Against these trends in culture viability, growth rate, and cell cycle state, we observed no significant trend in MAb BT32/A6 labeling of SK-MG-1 glioma cells as a function of culture split ratio (r = Ϫ0.303, p Ͼ 0.05, Fig.  6 ). The data failed to reject the null hypothesis that the slope of the regression line was zero as determined by Student's t-test. We concluded that MAb BT32/A6 labeling of SK-MG-1 is independent of culture viability, growth rate, and cell cycle state across the range of passage split ratios we studied.
Discussion
Satisfactory treatment of most solid tumors (for example, tumors of the breast, colon, or lung) remains an elusive clinical goal, but nowhere is this problem more apparent than in the management of malignant glioma, where the basic approach has changed little in the past 25 years despite monumental efforts to improve the outlook for patients with these tumors. The combination of subtotal resection, radiotherapy, and chemotherapy with carmustine (BCNU) remains the established standard treatment. Many of the surgical oncology principles that are applicable outside of the central nervous system (CNS), such as the concept of a wide resection margin, cannot be applied to malignant glioma. As a result, the tumor burden that remains at the completion of conventional therapy may be considerable, perhaps 10 6 or 10 7 cells. 20 There is currently no mechanism for effectively dealing with these remaining cells; however, it can be postulated that such a significantly reduced tumor burden may be a suitable candidate for adjunctive MAb therapy.
Some time ago, one of us (M.D.D.) undertook the development of a human MAb that could be used as an adjunct to therapy for malignant glioma, to localize and eradicate the tumor cells that remained at the completion of standard therapy. We speculated that an ideal antibody would recognize glioma-associated or -specific antigens not expressed on normal brain tissue. Such an antibody could be conjugated to a radioisotope if it did not internalize in the cell, or to a toxin if it did. In the present report, we describe a human IgM MAb that recognizes a glioma-associated antigen that resides on the surface of viable tumor cells capable of forming colonies in vitro and is unaffected by cell cycle state, cell growth rate, cell culture density, or culture viability.
The nature of the antigen recognized by MAb BT32/A6 was previously reported to be a cell surface glycolipid; 2 however, our group has recently found evidence that it may also reside on cell-surface proteins or glycoproteins (data not shown). Immunofluorescence studies of cultured normal human astrocytes labeled with MAb BT32/A6 were previously reported to be negative. 2 The expression of the antigen recognized by MAb BT32/A6 is exceptional in that is appears that virtually 100% of SK-MG-1 cells (as determined by flow cytometry) express this antigen, regardless of their culture density, culture viability, or cell cycle state. The reason this is so remarkable is that malignant gliomas are usually thought of as heterogeneous tumors, and it is exceptional to find a common biological thread among all cells in a given tumor. Indeed, heterogeneity is a common feature of all neoplastic tissues; it may arise through "normal" mechanisms or result from an increased genetic instability which is intrinsic to the cancer cell. 17 It has been suggested that in the strictest sense, the term "tumor heterogeneity" should be reserved for situations in which there are differences in cell lineage. 7 Cell cycle effects and other epigenetic phenomena add another level of complexity to the picture of tumor cell variability.
Few tumor-specific MAbs exist that recognize 100% of all neoplastic cells, even in a highly passaged line such as SK-MG-1. In an excellent study that used computerassisted cytofluorometry, Stavrou, et al., 26 reported on two such MAbs, MUC 8-22 and MUC 2-63, which recognize up to 100% of certain cultured astrocytoma and glioblastoma lines (for example, 86HG-63 and 86HG-39), although such observations were rare. The same group of authors found that the percentage of cells that showed antibody binding varied from one cell line to another and even within individual cell lines at different passage levels.
Once a primary brain tumor is adapted for growth in vitro, there may be a loss of specific antigenic markers (for example, glial fibrillary acidic protein) after only a few passages in culture, just as much of the original karyotypic heterogeneity of these tumors is lost after as few as 10 passages in culture. 23 Prolonged growth in vitro could significantly alter a tumor cell's antigenic repertoire compared to the original tumor in vivo.
One of the reasons the SK-MG-1 human glioma line was chosen for the present studies is that soon after the line was established, sera from the patient (AJ) who originally contributed the line was tested in an anti-C3 mixed hemadsorption assay against a panel of human and nonhuman, malignant and nonmalignant cell lines and found to absorb autologous reactivity of all astrocytomas, neuroblastomas, sarcomas, and most melanomas tested, but not carcinomas, normal tissue, or fetal brain. 19 Most of the cell lines included in the panel were well beyond the 10th passage in vitro, which suggests that the serum from patient AJ contained antibodies that recognize a common neuroectodermal tumor-associated, tumor-specific antigen, rather than some highly restricted antigen present only on autologous tumor cells for a few initial passages in vitro. It remains to be determined whether MAb BT32/A6 recognizes the same AJ antigen, or a related class of glioma-associated antigen, or something entirely different.
A human MAb, CLN-IgG, that recognizes a gliomaassociated antigen whose surface expression is influenced by cell cycle state has been reported by Kokunai, et al. 10 Expression of the antigen recognized by CLN-IgG was shown to be markedly increased on the surface of glioma cells in the G 2 /M phase of the cell cycle, but significantly reduced on cells in the G 0 /G 1 phase. These findings have important therapeutic implications, because most conven- tional adjuvant therapies (such as radiotherapy and chemotherapy) are directed toward cycling tumor cells, and it is among the more mitotically quiescent, noncycling cell populations that tumor stem cells are thought to reside.
14 If MAb-based tumor immunotherapy is to succeed, it must target tumor cells that are mitotically quiescent as well as those that are actively dividing. This means that the MAb must be directed to tumor-associated antigens that are present during all phases of the cell cycle and not just G 2 /M.
So far, there has been only one other report of a MAb directed to an astrocytoma-associated antigen that is expressed in a cell cycle-independent fashion 21 as demonstrated by flow cytometry. The particular MAb, designated M2, is a murine MAb that recognizes antigenic determinants expressed on a wide variety of CNS tumors, including juvenile astrocytomas, ependymomas, medulloblastomas, meningiomas, and oligodendrogliomas. The MAb M2 was also found to react with astrocytes in all areas of normal human adult brain, as well as with a small number of neurons and with fetal brain.
In conclusion, our human MAb, BT32/A6 recognizes a cell cycle-independent, glioma-associated antigen that is expressed on 100% of viable SK-MG-1 cells, but not on cultured normal human astrocytes. 2 Expression of the BT32/A6 antigen is unaffected by cell density, growth rate, or culture viability. It remains to be determined whether MAb BT32/A6 recognizes the AJ antigen or a related class of glioma-associated antigen. Future studies will therefore be directed at screening a large panel of cultured human cell lines, as well as frozen and paraffinembedded sections of human primary tumors and normal tissues. The results of these and other experiments will help determine the therapeutic suitability of MAb BT32/A6 in glioma patients.
